Will be interesting seeing early next year after meeting with FDA. If breakthrough status is granted there is every possibility this could be taken straight to market. Obviously there would still be some monitoring of patients but next year could get very exciting. We just don't know, we are all guessing at this stage. The only thing we know for certain is this company has not put a step out of place and as the results show they now how to conduct robust trials, unlike some other bio's.
Will be interesting seeing early next year after meeting with...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 221 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 1553 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |